Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price target raised by Guggenheim from $55.00 to $57.00 in a research note released on Thursday, MarketBeat reports. They currently have a buy rating on the stock. A number of other research analysts also recently issued reports on AMLX. Robert W. Baird boosted their price objective on […]

Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its price objective lifted by Needham & Company LLC from $292.00 to $310.00 in a research note published on Wednesday morning, Marketbeat.com reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. Other research analysts have also recently issued research reports about the stock. […]

Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its price target increased by Canaccord Genuity Group from $81.00 to $83.00 in a research report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other research firms have also weighed in on RARE. Wedbush lowered their price […]

Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its target price upped by Guggenheim from $40.00 to $55.00 in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other research firms have also recently issued reports on AMLX. Citigroup lifted their price objective on shares of […]

Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price target upped by Robert W. Baird from $28.00 to $52.00 in a research note published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock. A number of other research firms have also recently weighed in on AMLX. Wall Street Zen cut Amylyx Pharmaceuticals […]

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) had its price target lifted by equities research analysts at HC Wainwright from $34.00 to $55.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 65.26% from the stock’s current […]